223 related articles for article (PubMed ID: 22455721)
1. Helminth parasite proteomics: from experimental models to human infections.
Mutapi F
Parasitology; 2012 Aug; 139(9):1195-204. PubMed ID: 22455721
[TBL] [Abstract][Full Text] [Related]
2. Immunomics-Guided Antigen Discovery for Praziquantel-Induced Vaccination in Urogenital Human Schistosomiasis.
Pearson MS; Tedla BA; Becker L; Nakajima R; Jasinskas A; Mduluza T; Mutapi F; Oeuvray C; Greco B; Sotillo J; Felgner PL; Loukas A
Front Immunol; 2021; 12():663041. PubMed ID: 34113343
[TBL] [Abstract][Full Text] [Related]
3. Praziquantel treatment of individuals exposed to Schistosoma haematobium enhances serological recognition of defined parasite antigens.
Mutapi F; Burchmore R; Mduluza T; Foucher A; Harcus Y; Nicoll G; Midzi N; Turner CM; Maizels RM
J Infect Dis; 2005 Sep; 192(6):1108-18. PubMed ID: 16107967
[TBL] [Abstract][Full Text] [Related]
4. Cytokine responses to the anti-schistosome vaccine candidate antigen glutathione-S-transferase vary with host age and are boosted by praziquantel treatment.
Bourke CD; Nausch N; Rujeni N; Appleby LJ; Trottein F; Midzi N; Mduluza T; Mutapi F
PLoS Negl Trop Dis; 2014 May; 8(5):e2846. PubMed ID: 24810615
[TBL] [Abstract][Full Text] [Related]
5. Population level changes in schistosome-specific antibody levels following chemotherapy.
Fukushige M; Mutapi F; Woolhouse MEJ
Parasite Immunol; 2019 Jan; 41(1):e12604. PubMed ID: 30467873
[TBL] [Abstract][Full Text] [Related]
6. Predicted impact of mass drug administration on the development of protective immunity against Schistosoma haematobium.
Mitchell KM; Mutapi F; Mduluza T; Midzi N; Savill NJ; Woolhouse ME
PLoS Negl Trop Dis; 2014; 8(7):e3059. PubMed ID: 25079601
[TBL] [Abstract][Full Text] [Related]
7. Immuno-epidemiology of human Schistosoma haematobium infection: preferential IgG3 antibody responsiveness to a recombinant antigen dependent on age and parasite burden.
Mutapi F; Mduluza T; Gomez-Escobar N; Gregory WF; Fernandez C; Midzi N; Maizels RM
BMC Infect Dis; 2006 Jun; 6():96. PubMed ID: 16764709
[TBL] [Abstract][Full Text] [Related]
8. Day-to-day variation of egg output and schistosome circulating antigens in urine of Schistosoma haematobium-infected school children from Gabon and follow-up after chemotherapy.
Van Etten L; Kremsner PG; Krijger FW; Deelder AM
Am J Trop Med Hyg; 1997 Sep; 57(3):337-41. PubMed ID: 9311646
[TBL] [Abstract][Full Text] [Related]
9. Schistosome vaccines: current progress and future prospects.
Sher A; James SL; Correa-Oliveira R; Hieny S; Pearce E
Parasitology; 1989; 98 Suppl():S61-8. PubMed ID: 2498828
[TBL] [Abstract][Full Text] [Related]
10. Schistosoma bovis as an immunological analogue of S. haematobium.
Agnew AM; Murare HM; Lucas SB; Doenhoff MJ
Parasite Immunol; 1989 Jul; 11(4):329-40. PubMed ID: 2506507
[TBL] [Abstract][Full Text] [Related]
11. The effect of treatment on the age-antibody relationship in children infected with Schistosoma mansoni and Schistosoma haematobium.
Mutapi F; Mduluza T; Ndhlovu PD
Mem Inst Oswaldo Cruz; 2002; 97 Suppl 1():173-80. PubMed ID: 12426616
[TBL] [Abstract][Full Text] [Related]
12. Effect of treating Schistosoma haematobium infection on Plasmodium falciparum-specific antibody responses.
Reilly L; Magkrioti C; Mduluza T; Cavanagh DR; Mutapi F
BMC Infect Dis; 2008 Nov; 8():158. PubMed ID: 19014683
[TBL] [Abstract][Full Text] [Related]
13. Immune attrition of adult schistosomes.
Agnew AM; Murare HM; Doenhoff MJ
Parasite Immunol; 1993 May; 15(5):261-71. PubMed ID: 8332382
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy accelerates the development of acquired immune responses to Schistosoma haematobium infection.
Mutapi F; Ndhlovu PD; Hagan P; Spicer JT; Mduluza T; Turner CM; Chandiwana SK; Woolhouse ME
J Infect Dis; 1998 Jul; 178(1):289-93. PubMed ID: 9652458
[TBL] [Abstract][Full Text] [Related]
15. Benefits of annual chemotherapeutic control of schistosomiasis on the development of protective immunity.
Chisango TJ; Ndlovu B; Vengesai A; Nhidza AF; Sibanda EP; Zhou D; Mutapi F; Mduluza T
BMC Infect Dis; 2019 Mar; 19(1):219. PubMed ID: 30832614
[TBL] [Abstract][Full Text] [Related]
16. Human Schistosoma haematobium antifecundity immunity is dependent on transmission intensity and associated with immunoglobulin G1 to worm-derived antigens.
Wilson S; Jones FM; van Dam GJ; Corstjens PL; Riveau G; Fitzsimmons CM; Sacko M; Vennervald BJ; Dunne DW
J Infect Dis; 2014 Dec; 210(12):2009-16. PubMed ID: 25001462
[TBL] [Abstract][Full Text] [Related]
17. CD16 expression on monocytes in healthy individuals but not schistosome-infected patients is positively associated with levels of parasite-specific IgG and IgG1.
Appleby LJ; Nausch N; Erskine L; Bourke CD; Rujeni N; Midzi N; Mduluza T; Mutapi F
PLoS Negl Trop Dis; 2014 Aug; 8(8):e3049. PubMed ID: 25101623
[TBL] [Abstract][Full Text] [Related]
18. A monoclonal antibody against Schistosoma haematobium soluble egg antigen: efficacy for diagnosis and monitoring of cure of S. haematobium infection.
Salah F; Demerdash Z; Shaker Z; El Bassiouny A; El Attar G; Ismail S; Badir N; El Din AS; Mansour M
Parasitol Res; 2000 Jan; 86(1):74-80. PubMed ID: 10669141
[TBL] [Abstract][Full Text] [Related]
19. Break Out: urogenital schistosomiasis and Schistosoma haematobium infection in the post-genomic era.
Brindley PJ; Hotez PJ
PLoS Negl Trop Dis; 2013; 7(3):e1961. PubMed ID: 23556007
[No Abstract] [Full Text] [Related]
20. Protective immunity to Schistosoma haematobium infection is primarily an anti-fecundity response stimulated by the death of adult worms.
Mitchell KM; Mutapi F; Savill NJ; Woolhouse ME
Proc Natl Acad Sci U S A; 2012 Aug; 109(33):13347-52. PubMed ID: 22847410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
